KPV: What the Research Says About the alpha-MSH Tripeptide
A three-residue fragment of alpha-MSH studied for NF-kB modulation and mucosal inflammation, without the pigmentation activity of the parent hormone.
KPV is the smallest peptide in most research catalogs — three amino acids — and it comes from one of the largest. It is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, and the reason it attracted attention is that it appears to keep the anti-inflammatory behaviour of the parent hormone without the pigmentation activity.
Everything below describes published preclinical and in-vitro research. It is not a therapeutic claim, not medical advice, and not a statement about effects in humans.
What it is
KPV is Lys-Pro-Val: lysine, proline, valine. Those are residues 11 to 13 of alpha-MSH, a 13-residue hormone derived from proopiomelanocortin. At roughly 342 Da it is about a quarter the mass of the parent.
The split matters. Alpha-MSH acts on melanocortin receptors, which is where pigmentation comes from — the same receptor family Melanotan II works through. The published work on KPV describes anti-inflammatory activity that does not appear to require those receptors, which is what makes it a separate research subject rather than a weaker version of the same thing.
Reported mechanisms
- NF-κB signalling — the most consistently reported theme. Studies describe interference with nuclear translocation of NF-κB, the transcription factor that switches on much of the inflammatory response.
- Mucosal models — a substantial part of the literature concerns intestinal epithelium, with published work on colitis models.
- Receptor-independent entry — several papers describe uptake by epithelial cells through the PepT1 transporter rather than a melanocortin receptor, which would explain activity in tissues with little melanocortin expression.
- Antimicrobial behaviour — a smaller body of work describes direct effects on bacterial and fungal growth in culture.
Practical notes
| Sequence | Lys-Pro-Val (KPV) |
|---|---|
| Length | 3 amino acids |
| Molecular weight | ~342 Da |
| Parent molecule | alpha-MSH, residues 11–13 |
| Primary reported mechanism | NF-κB modulation |
| Typical vial size | 10 mg |
At three residues KPV is short enough that its analysis should be unambiguous — a clean single peak and a mass within a fraction of a Dalton of 342. There is very little room for a deletion sequence to hide in a tripeptide, so a messy certificate on this compound is harder to explain than on a long chain.
Reading this literature critically
- Most published work is in cell culture or rodent colitis models. Extrapolating to any other context is not supported by the data.
- KPV is not an approved medicine in the European Union or elsewhere.
- The PepT1 uptake route is reported rather than settled, and papers differ on how much of the observed activity it accounts for.
- Because the parent hormone has well-known receptor activity, some secondary sources attribute alpha-MSH findings to KPV. Check which molecule a given paper actually used.
Handling
Supplied as lyophilised powder, stable at room temperature before reconstitution and refrigerated after. Short peptides are generally less prone to aggregation than long chains, but the same handling rules apply: swirl rather than shake, keep it out of direct light, and label the vial with compound, concentration and date. Our reconstitution calculator covers the concentration arithmetic.
Every batch we supply is analysed by an independent laboratory for HPLC purity and mass-spectrometric identity, with batch-matched certificates available on request. See the KPV 10mg product page for full molecular data, or the rest of recovery and repair research.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.